Floatz logo

Vildagliptin

Kidney Insufficiency

Cairo UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Kidney Insufficiency cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Anna Cruceta
Phase 4BBB
DEXAMETHASONE
Augusta University
Phase 3BB
Midodrine
Anna Cruceta
Phase 4BB
Envarsus Product
University of Alberta
Phase 4BB
Empagliflozin
University Hospital, Basel, Switzerland
Phase 4BB

View all 50 →

Same molecule, other indications

Vildagliptin is also rated in:

type 2 diabetes mellitusDormant
BBB
Indicative ·
72 / 100
View asset →
inflammatory diseaseDormant
BB
Indicative ·
69 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →